The Cooper Companies, Inc. (COO): análise e preço justo

Números-chave da The Cooper Companies, Inc.

Capitalização

11,2 mM US$

P/E (preço ÷ lucro)

31,5

Dividendo (yield)

Não paga

Crescimento das vendas

8,5%

por ano, em 9 anos

Margem de lucro

9,2%

Testes de qualidade

4/8

Contas do ano fiscal de 2025, entregues à SEC.

Sobre a The Cooper Companies, Inc.

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.